Addition of 5-fluorouracil to first-line induction chemotherapy with docetaxel and cisplatin before concurrent chemoradiotherapy does not improve survival in locoregionally advanced nasopharyngeal carcinoma

• DOI: 10.18632/oncotarget.20017
• Publication Date: 2017-08-07T22:49:41Z
• Authors: Wang Fangzheng; Jiang Chuner; Wang Lei; Yan Fengqin; Ye Zhimin; Sun Quanquan; Liu Tongxin; Xu Min; Wu Peng; Long Bin; Rihito Aizawa; Masoto Sakamoto; Fu Zhenfu
• Keywords: Chemoradiotherapy

// Wang Fangzheng 1, 2, 3, * , Jiang Chuner 4, Lei 2 Yan Fengqin Ye Zhimin Sun Quanquan Liu Tongxin Xu Min 5 Wu Peng 6 Long Bin 7 Rihito Aizawa 8 Masoto Sakamoto 3 and Fu Zhenfu 1 Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022, People’s Republic China Key Laboratory Radiology, Japanese Red Cross Fukui Fukui, 918-8501 Japan 4 Breast Tumor Surgery, Physics, Pathology, Nuclear Medicine, Oncology Image-applied Therapy, Graduate School Kyoto University, 606-8507, Kyoto, These authors contributed equally to this work Correspondence to: Zhenfu, email: [e-mail] Keywords: nasopharyngeal carcinoma, induction chemotherapy, concurrent chemoradiotherapy, toxicity, prognosis Received: June 05, 2017      Accepted: July 25, Published: August 07, 2017 ABSTRACT Although a multicenter, randomized study indicated that chemotherapy (IC) with docetaxel/cisplatin/fluorouracil (TPF) before chemoradiotherapy (CCRT) improves survival outcomes, it remains unclear whether TPF is the best IC regimen for treating locoregionally advanced carcinoma (NPC). Our aim was compare efficacy toxicities vs. docetaxel/cisplatin (TP) followed by CCRT in patients NPC. One hundred thirty-two NPC received 21-day cycles either or TP. Both were intensity-modulated radiotherapy cisplatin treatment every weeks. Three-year rates locoregional relapse-free survival, distant metastasis-free progression-free overall respectively 96.4%, 87.7%, 86.0%, 94.7% arm 90.3%, 91.9%, 85.2%, 92.0% TP arm. There no differences between two arms. Multivariate analysis revealed not an independent prognostic factor any outcome. However, experienced fewer grade 3/4 toxicities. In sum, docetaxel associated similar less toxicity than regimen. Addition fluorouracil plus therefore recommended